Search for stocks, analyses, updates

Search Results for:

Revolution Medicines, Inc.
Biotechnology / Precision Oncology
USA

Stock: Revolution Medicines

Revolution Medicines is one of the most exciting biotech stocks for 2026. Strong Phase 3 data and a leading RAS
Further Neutral
Revolution Medicines
Healthcare
USA

Valuation Analysis: Revolution Medicines

Revolution Medicines develops innovative cancer therapies against RAS mutations and is one of the leading biotechnology companies in the field
Further Neutral
Johnson & Johnson
Healthcare
USA

Valuation Analysis: Johnson & Johnson

Johnson & Johnson is one of the world's leading healthcare companies. The company benefits from a strong position in pharmaceuticals
Further Neutral
Johnson & Johnson
Healthcare
USA

Stock: Johnson & Johnson

Thanks to a strong pipeline, robust cash flows and a defensive business model, Johnson & Johnson remains a high-quality healthcare
Further Neutral
Weekly Update

Weekly Market Overview – June 29–July 5, 2026

The healthcare sector remains in the lead, while technology and defense stocks are regaining strength. Positive impulses for the UMBRELLA
Further Neutral
Tesla
Valuation Analysis
USA

Valuation Analysis: Tesla

Tesla is increasingly evolving from an electric car manufacturer into an AI, robotics, and energy company. This analysis assesses opportunities,
Further Neutral
Tesla, Inc.
Automotive, Technology & Energy
USA

Stock: Tesla

Tesla is increasingly evolving from an electric car manufacturer into an AI, robotics, and energy company. This analysis assesses opportunities,
Further Neutral
AstraZeneca PLC
Pharmaceuticals & Biotechnology
United Kingdom

Stock: AstraZeneca PLC

AstraZeneca is one of the world's leading pharmaceutical companies. Growth, strong cash flows, and an innovative drug pipeline support long-term
Further Neutral
Bayer AG
Pharmaceuticals, Chemicals & Biotechnology
Germany

Valuation Analysis: Bayer AG

Bayer is making operational progress with improving profitability. However, litigation and high debt continue to weigh on the outlook.
Further Neutral
Bayer
Pharmaceuticals, Chemicals & Biotechnology
Germany

Stock: Bayer AG

Bayer is making operational progress with improving profitability. However, litigation and high debt continue to weigh on the outlook.
Further Neutral
Eli Lilly and Company
Valuation Analysis
USA

Valuation Analysis: Eli Lilly and Company

Eli Lilly remains one of the biggest beneficiaries of the GLP-1 boom. Strong fundamentals, growth in Mounjaro and Zepbound, and
Further Neutral
Eli Lilly
Pharmaceuticals
USA

Stock: Eli Lilly and Company

Eli Lilly is one of the leading pharmaceutical companies and benefits significantly from the growth in GLP-1 drugs for diabetes
Further Neutral